Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duvelisib + chidamide
- Development stage
- Unknown
- Lead developer
- Verastem Oncology
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Duvelisib + chidamide is a combination of two small molecule drugs used in investigational regimens for hematologic malignancies. Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma isoforms, which are critical for B-cell receptor signaling and immune cell function. It is approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)[1][3][5]. Chidamide is an oral histone deacetylase (HDAC) inhibitor that modulates chromatin structure to suppress tumor cell growth and induce apoptosis. It has been approved in China for relapsed or refractory peripheral T-cell lymphoma and has shown activity in other hematologic cancers[6][7]. The combination targets both PI3K-mediated survival pathways and epigenetic regulation to enhance anti-tumor effects.
- Brand names
- EpidazaCopiktra
- Other names
- chidamide + duvelisibduvelisib combined with chidamide
02
Targets
HDAC11 (Histone Deacetylase 11)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CA (Phosphoinositide 3-kinase alpha)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC8 (Histone Deacetylase 8)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)NAMPT
Beyond the preview
Go deeper on duvelisib + chidamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duvelisib + chidamide.